Document:

Exhibit 10.6

                      AMENDMENT TO FIRST LICENSE AGREEMENT

      This Amendment, dated as of this 3rd day of March, 2005 (this "AMENDMENT")
to the License Agreement dated March 19, 2001 (the "FIRST LICENSE AGREEMENT"),
is made by and between Cytomedix, Inc. ("LICENSOR") and DePuy Spine, Inc. (f/k/a
DePuy AcroMed, Inc.) (hereinafter "LICENSEE"). Capitalized terms used herein and
not otherwise defined shall have the meaning set forth in the FIRST LICENSE
AGREEMENT.

      WHEREAS, LICENSOR and LICENSEE are contemporaneously entering into a
SECOND LICENSE AGREEMENT (the "SECOND LICENSE AGREEMENT") whereby LICENSOR is
granting to LICENSEE non-exclusive worldwide exploitation rights to practice and
utilize the PATENTS in other fields of use requested by LICENSEE;

      WHEREAS, LICENSOR and LICENSEE desire to modify the terms of the FIRST
LICENSE AGREEMENT to eliminate the exclusivity provisions attendant to
LICENSEE'S rights to practice and utilize the PATENTS in respect of the LICENSED
FIELD and to make such other amendments to the FIRST LICENSE AGREEMENT as are
consistent therewith;

      NOW, THEREFORE, in consideration of the mutual covenants and promises
contained in this AMENDMENT, and for other good and valuable consideration, the
receipt of which is hereby acknowledged, the parties agree as follows:

      1.    Section 1.3: Reference to "Section 1.8" is changed to "Section 1.5."

      2.    Section 1.5: The last sentence of Section 1.5 is deleted in its
            entirety and replaced with the following:

            The term "chronic non-healing wounds" means (i) any venous stasis,
            pressure (i.e., decubitus), or diabetic foot ulcers or (ii) any
            wounds lasting 30 days or longer.

      3.    Section 1.6: Section 1.6 is amended to read:

            1.6 AFFILIATES shall mean entities owned and organized under DePuy,
            Inc. including, but not limited to DePuy Orthopaedics, Inc., DePuy
            International, Ltd. and its affiliates, DePuy ACE, Inc., and Codman
            & Shurtleff, Inc. or an entity that directly or indirectly controls,
            is controlled by, or is under common control with, the entity
            specified. The term "owned" means the legal, beneficial or equitable
            ownership directly or indirectly of more than 50% of the aggregate
            of all voting equity interests rights in such entity.

      4.    Section 2.0:

      a.    Section 2.0 is deleted in its entirety and replaced with the
            following:

            LICENSOR hereby grants to LICENSEE, to the extent of the LICENSED
            FIELD and LICENSED TERRITORY, a license under the PATENTS to fully
            practice the PATENTS, including the right to make, have made, use,
            offer for sale, sell and import PRODUCTS and promote the methods and
            compositions recited in the claims of PATENTS using PRODUCTS in the
            LICENSED FIELD. LICENSOR recognizes that LICENSEE may also practice
            the PATENTS by promoting and selling through its AFFILIATES and
            DISTRIBUTORS. This license also includes a right in purchasers and
            users of PRODUCT to fully practice PATENTS within the LICENSED
            FIELD, with such PRODUCT. Additionally, notwithstanding anything in
            the FIRST LICENSE AGREEMENT to the contrary, CYTOMEDIX releases
            LICENSEE and all purchasers and users of purchased PRODUCT for any
            liability to CYTOMEDIX of any kind whatsoever (whether direct or
            indirect, or known or unknown) arising from any past sale or use of
            purchased PRODUCT outside of the LICENSED FIELD. LICENSEE
            acknowledges and agrees that no license is granted or implied under,
            and agrees not to practice under the PATENTS outside the LICENSED
            FIELD. Furthermore, LICENSOR releases LICENSEE from any liability to
            LICENSOR of any kind whatsoever (including breach of contract)
            arising from purchasers of PRODUCT using the PRODUCT outside the
            LICENSED FIELD of the FIRST LICENSE AGREEMENT and the ADDITIONAL
            FIELDS of the SECOND LICENSE AGREEMENT provided that LICENSEE does
            not promote sales of PRODUCT outside the LICENSED FIELD of the FIRST
            LICENSE AGREEMENT and the ADDITIONAL FIELDS of the SECOND LICENSE
            AGREEMENT.

<PAGE>

      5.    Section 2.1: Section 2.1 is deleted in its entirety and replaced
            with the following:

            The license granted pursuant to Section 2.0 hereof shall be
            non-exclusive for the remaining term of this Agreement.

      6.    Article III: The following sections 3.2 is added to Article III:

            3.2 In the event that LICENSOR enters into any agreement with a
            third party whereby LICENSOR grants the third party a license under
            the PATENTS, and said third party is obligated under said license to
            pay LICENSOR a royalty rate that is less than the six and one-half
            percent (6.5%) royalty rate payable under Sections 3.1 and 5.3
            hereof (hereinafter, the "More Favorable Royalty Rate), then the
            royalty rate of Sections 3.1 and 5.3 hereof shall be deemed,
            effective as of the date of such third-party license agreement, to
            be the More Favorable Royalty Rate.

      7.    Article IV: Minimum Royalties: Sections 4.0 and 4.1 are deleted in
            their entirety.

      8.    Article V: Sublicensing.

            a.    Section 5.0: The second sentence of Section 5.0 is deleted in
                  its entirety and replaced with the following:

            This sublicense also includes a right in purchasers and users of the
            purchased PRODUCT to fully practice PATENTS within the ADDITIONAL
            LICENSED FIELDS with such PRODUCT. The LICENSEE shall not have the
            right to sublicense to any other third party.

            b.    Section 5.5: Section 5.5 is deleted in its entirety.

      9.    Article VI: Payments

            a.    Section 6.3: Section 6.3 is deleted in its entirety.

            b.    Section 6.4: Deleted from Section 6.4 is the parenthetical
                  expression "(including minimum royalties of the year in which
                  the Agreement is terminated)."

      10.   Article VII: Confidentiality: A new Section 7.03 shall be added,
            which provides as follows:

                  7.03 Information disclosed by LICENSEE to LICENSOR or
            otherwise obtained by LICENSOR under this Agreement shall only be
            used by LICENSOR for the purpose of determining compliance under
            this Agreement by LICENSEE, sublicensees, or users or purchasers of
            PRODUCT, and not for any other purpose

      11.   Section 8.2: Section 8.2 is deleted in its entirety.

<PAGE>

      12.   Article X: Termination

            a.    Section 10.1: Deleted from Section 10.1 is the phrase "for up
                  to ninety (90) days".

            b.    Section 10.3.b: Deleted from Section 10.3.b is the
                  parenthetical phrase "(including minimum royalties)".

            c.    Section 10.6: Section 10.6 is deleted in its entirety and
                  replaced with the following:

            LICENSEE shall have a right to terminate this Agreement upon 180
            days written notice.

      13.   Section 11.0 through Section 11.5: Sections 11.0 through 11.5 of
            Article XI are deleted in their entirety and replaced with the
            following:

            11.0 LICENSOR may, at its own expense, bring suit or take any other
            action it deems appropriate in its sole and absolute discretion
            against any infringer in the LICENSED FIELD and LICENSOR shall be
            entitled to all past, present, or future recoveries that in any way
            result from or relate to such suit or action.

      14.   Article XII: Records. In Section 12.0, the phrase "records of all
            operations affecting payments hereunder" is replaced with "records
            showing the sales or other disposition of PRODUCT sold or otherwise
            disposed of under the license herein granted in sufficient detail to
            enable the compliance with the terms of this FIRST LICENSE AGREEMENT
            to be determined."

      15.   Section 21.0: The addresses in Section 21.0 to which notices to the
            LICENSOR shall be supplied are replaced with the following:

            LICENSOR:          Cytomedix, Inc.
                               416 Hungerford Drive, Suite 330
                               Rockville, Maryland 20850
                               Attention: Dr. Kshitij Mohan, CEO

            With a copy to:    Steven R. Jakubowski
                               Robert F. Coleman & Associates
                               77 West Wacker Drive, Suite 4800
                              Chicago, Illinois 60601

      15.   Section 22.0: Section 22.0 is deleted in its entirety and replaced
            with the following:

            To the extent legally permissible and/or legally mandated, LICENSEE
            agrees to mark its brochures for the items listed in Appendix B
            (revised and attached hereto) and improvements thereof with the
            following: "Certain products shown in this brochure are sold subject
            to a License Agreement with Cytomedix Inc., and are not licensed for
            use in treating chronic non-healing wounds (i.e., any venous stasis,
            decubitus, or diabetic foot ulcers, or any other wounds lasting 30
            days or longer).

<PAGE>

      IN WITNESS WHEREOF, the parties have caused this AMENDMENT to be duly
executed as of the date first mentioned above via their telefaxed signatures,
which shall have the same import and effect as if signed originally.

LICENSOR                           LICENSEE
Cytomedix, Inc.                    DePuy Spine, Inc. (f/k/a DePuy AcroMed, Inc.)

By:  Kshitij Mohan, Ph.D.          By:  Earl Fender

Name:  Kshitij Mohan, Ph.D         Name:  Earl Fender

Its:  Chief Executive Officer      Its:  Worldwide President

<PAGE>

                                   APPENDIX B
                             (Schedule of Products)

SEPARATORS

2761-02-020       SYMPHONY II FS-20 Blood Draw and Processing Components

2761-02-060       SYMPHONY II FS-60 Blood Draw and Processing Components

2761-02-120       SYMPHONY II FS-120 Blood Draw and Processing Components

2760-40-101       SYMPHONY Process Disposable-One

2760-40-102       SYMPHONY Process Disposable-Two

Disposable Processing Kits contain the items required for containing blood
during processing in the centrifuge

CAPITAL

2761-02-000       SYMPHONY II Centrifuge with Balance Weight Set

2760-40-000       SYMPHONY Centrifuge

APPLICATORS/MIXERS

2760-40-202       SYMPHONY Spray Applicator

2760-40-204       SYMPHONY Dual Lumen Applicator

2760-50-000       SYMPHONY GDS Standard Kit

2760-50-100       SYMPHONY GDS Manifold KitExhibit 10.7

                            SECOND LICENSE AGREEMENT

      This SECOND LICENSE AGREEMENT, dated as of this 3rd day of March, 2005
(this "SECOND LICENSE AGREEMENT") is made by and between Cytomedix, Inc.
("LICENSOR") and DePuy Spine, Inc. (f/k/a DePuy AcroMed, Inc.) ("LICENSEE").
Capitalized terms used herein shall have the meaning set forth herein.

      WHEREAS,

A. LICENSOR co-owns certain patents with the University of Minnesota pertaining
to damaged tissue treatment methods, processes, and compositions. The University
of Minnesota has assigned all rights to the certain patents, but has retained a
non-exclusive perpetual license solely in connection with not-for-profit
research and teaching.

B. WHEREAS, LICENSOR and LICENSEE entered into a license agreement dated March
19, 2001 (the "FIRST LICENSE AGREEMENT"), whereby LICENSOR granted LICENSEE the
worldwide exploitation rights to practice and utilize the PATENTS in certain
fields of use (the "ORIGINAL LICENSED FIELDS") on the terms and conditions set
forth in the FIRST LICENSE AGREEMENT.

C. WHEREAS, LICENSEE desires the non-exclusive worldwide right to practice and
utilize the PATENTS in the ADDITIONAL LICENSED FIELDS;

D. WHEREAS, LICENSOR desires to grant to LICENSEE non-exclusive worldwide
exploitation rights to practice and utilize the PATENTS in the ADDITIONAL
LICENSED FIELDS on the terms and conditions set forth in this SECOND LICENSE
AGREEMENT;

      NOW, THEREFORE, in consideration of the mutual covenants and promises
contained in this SECOND LICENSE AGREEMENT, and for other good and valuable
consideration, the receipt of which is hereby acknowledged, the parties agree as
follows:

I.    Definitions

      1.00 PATENT or PATENTS means the patents and/or patent applications listed
in Appendix AA.

      1.01 LICENSED TERRITORY means the entire world.

      1.02 ADDITIONAL LICENSED FIELDS means all fields other than (i) the
LICENSED FIELD of the FIRST LICENSE AGREEMENT and (ii) the treatment of "chronic
non-healing wounds." For purposes of this SECOND LICENSE AGREEMENT, the term
"chronic non-healing wounds" means (i) any venous stasis, decubitus, or diabetic
foot ulcers or (ii) any wounds lasting 30 days or longer.

      1.03 PRODUCT shall mean any LICENSEE device marketed or promoted by
LICENSEE as being for producing or applying compositions including platelets
(which includes, but is not limited to, platelet concentrate) to facilitate
healing and used in all ADDITIONAL LICENSED FIELDS. Any LICENSEE device which is
marketed by LICENSEE without direct or indirect reference to platelets or
platelet releasate shall not be considered a PRODUCT. Notwithstanding the above,
for the term of this Agreement, the items listed in Appendix BB and replacements
of the centrifuge and separator products will be considered PRODUCTS
irrespective of the LICENSEE'S marketing activities thereon. LICENSEE reserves
the right to revise the items listed in Appendix BB subject to LICENSOR'S
written consent.

      1.04 NET SALES PRICE shall mean LICENSEE'S invoice price to customers,
AFFILIATES, or DISTRIBUTORS, f.o.b. factory, after deduction of freight, taxes
and agent's commissions. PRODUCTS that are used only by LICENSEE for sales
demonstration purposes shall have a zero dollar value for NET SALES PRICE.
PRODUCTS that are not sold to an end user, but are disposed of by LICENSEE due
to obsolescence, damage or other similar conditions shall have a zero dollar
value for NET SALES PRICE. NET SALES PRICE for the purposes of computing
royalties under this Agreement shall never be less than LICENSEE'S cost to
manufacture, determined by LICENSEE'S customary accounting practices plus five
percent (5%).

<PAGE>

      a.    capital PRODUCT

            i.    disposable allocation

            In the instance wherein LICENSEE disposes of a CAPITAL PRODUCT (such
      as a centrifuge) to a third party and receives full consideration therefor
      solely by explicitly adding a capital allocation therefor to invoices for
      the sales of disposable PRODUCTS to the third party, the royalty due for
      disposal of the capital PRODUCT shall be included in the royalty due upon
      the disposable PRODUCTS (such as a separator).

            ii.   outright capital PRODUCT sales

            In the instance wherein the capital PRODUCT is sold outright, the
      royalty shall be ten dollars ($10.00) for such PRODUCTS sold to a U.S.
      customer, and five dollars ($5.00) for such PRODUCTS sold to non-U.S.
      customers.

      b.    Non-US AFFILIATE sales of disposables

            For LICENSEE'S non-US sales to AFFILIATES, the NET SALES PRICE will
      be LICENSEE'S transfer price to its AFFILIATES, but in no event will be
      less than cost to manufacture determined by LICENSEE'S customary
      accounting practices plus five percent (5%).

      c.    Applicators/Mixers

            Royalties for all other products marketed and sold by LICENSEE in
      the ADDITIONAL LICENSED FIELDS shall not require further fee and no
      additional payment shall be made over the flat fee payments made pursuant
      to Section 1.4.c of the FIRST LICENSE AGREEMENT.

      1.05 Intentionally Omitted

      1.06 AFFILIATES shall mean entities owned and organized under DePuy, Inc.
including, but not limited to DePuy Orthopaedics, Inc., DePuy International,
Ltd. and its affiliates, DePuy ACE, Inc., and Codman & Shurtleff, Inc., or an
entity that directly or indirectly controls, is controlled by, or is under
common control with, the entity specified. The term "owned" means the legal,
beneficial or equitable ownership directly or indirectly of more than 50% of the
aggregate of all voting equity interests rights in such entity.

      1.07 DISTRIBUTORS shall mean an entity which is not an AFFILIATE but which
contracts with LICENSEE or an AFFILATE to either a) provide promotion, sales and
distribution services under the name of LICENSEE or an AFFILATE respecting
PRODUCT in exchange for commissions, or b) buys PRODUCT from LICENSEE or an
AFFILATE for resale under the name of LICENSEE or an AFFILATE.

<PAGE>

II. LICENSE GRANT

2.00 LICENSOR hereby grants to LICENSEE, to the extent of the ADDITIONAL
LICENSED FIELDS and LICENSED TERRITORY, a license under PATENTS, to fully
practice PATENTS, including the right to make, have made, use, offer for sale,
sell and import PRODUCTS and promote the methods and compositions recited in the
claims of PATENTS using PRODUCTS in the ADDITIONAL LICENSED FIELDS. LICENSOR
recognizes that LICENSEE may also practice the PATENTS by promoting and selling
through its AFFILIATES and DISTRIBUTORS. This license also includes a right in
purchasers and users of the purchased PRODUCT to fully practice PATENTS within
the ADDITIONAL LICENSED FIELDS with such PRODUCT. LICENSEE acknowledges and
agrees that no license is granted or implied hereunder outside the ADDITIONAL
LICENSED FIELDS and LICENSED TERRITORY. Furthermore, LICENSOR releases LICENSEE
from any liability to LICENSOR of any kind whatsoever (including breach of
contract) arising from purchasers of PRODUCT using the PRODUCT outside the
LICENSED FIELD of the FIRST LICENSE AGREEMENT and the ADDITIONAL FIELDS of the
SECOND LICENSE AGREEMENT provided that LICENSEE does not promote sales of
PRODUCT outside the LICENSED FIELD of the FIRST LICENSE AGREEMENT and the
ADDITIONAL FIELDS of the SECOND LICENSE AGREEMENT.

      2.01 The license granted pursuant to Section 2.00 hereof shall be
non-exclusive for the term of this Agreement.

III.  LICENSE FEES AND ROYALTIES

      3.00 No upfront payments shall be paid by LICENSEE for practicing the
PATENTS within the ADDITIONAL LICENSED FIELDS.

      3.01 LICENSEE shall pay to LICENSOR six and one-half percent (6.5%), after
the effective date, of the NET SALES PRICE ("Royalty") of all PRODUCTS sold or
otherwise disposed of under the license granted under Section 2.00 of this
Agreement in jurisdictions having valid, unexpired, and enforceable U.S. or
foreign PATENTS where the PRODUCT is made, used, sold, or offered for sale.

      3.02 In the event that LICENSOR enters into any agreement with a third
party whereby LICENSOR grants the third party a license under the PATENTS, and
said third party is obligated under said license to pay LICENSOR a royalty rate
that is less than the six and one-half percent (6.5%) royalty rate payable under
Sections 3.01 and 5.03 hereof (hereinafter, the "More Favorable Royalty Rate),
then the royalty rate of Sections 3.01 and 5.03 hereof shall be deemed,
effective as of the date of such third-party license agreement, to be the More
Favorable Royalty Rate.

      3.03 Commencing in respect of royalties payable for the second calendar
quarter of 2005 and continuing through the termination of this Agreement,
LICENSEE shall be entitled to take as a credit against royalty payments made
under any agreement with LICENSOR in an amount as provided in Section 6.06
hereof.

IV.   MINIMUM ROYALTIES

      4.00 There shall be no minimum royalties payable under this SECOND LICENSE
AGREEMENT for practice of the PATENTS in the ADDITIONAL LICENSED FIELDS.

      4.01 Intentionally omitted.

V.    SUBLICENSING

      5.00 LICENSEE shall have the right to sublicense to AFFILIATES and
DISTRIBUTORS. This sublicense also includes a right in purchasers and users of
the purchased PRODUCT to fully practice PATENTS within the ADDITIONAL LICENSED
FIELDS with such PRODUCT. The LICENSEE shall not have the right to sublicense to
any other third party.

      5.01 LICENSEE shall supply LICENSOR with a copy of each such sublicense
agreement within thirty (30) days after the execution of the sublicense
agreement.

      5.02 The royalty for sublicensees shall be no less than that set forth for
LICENSEE in Section 3.01, above.

<PAGE>

      5.03 LICENSEE shall pay to LICENSOR six and one-half percent (6.5%) of any
and all net sales made by sublicensors of PRODUCTS. For purposes of calculating
the amount due to LICENSOR under this Section 5.03, sales of products by
sublicensors shall be made using the definition of NET SALES PRICE and PRODUCT
or PRODUCTS. Amounts payable under this Section 5.02 shall be made to LICENSOR
quarterly as provided in Section 6.00.

      5.04 If this Agreement is terminated, LICENSEE shall immediately assign
all of its right, title, and interest to all sublicenses to LICENSOR, including
the right to receive all income from sublicensees. LICENSEE shall, prior to
execution of each sublicense, make the sublicense aware of this contingency.

      5.05 Intentionally omitted.

VI.   PAYMENTS

      6.00 LICENSEE shall pay all amounts due pursuant to Sections 3.01 and 5.03
("Royalty") quarterly. Within thirty (30) days after the end of each calendar
quarter, LICENSEE shall (a) pay LICENSOR the Royalty owed by LICENSEE for such
calendar quarter, and (b) provide LICENSOR with a written report setting forth
the NET SALES PRICE with respect to Products for the applicable quarter.
LICENSEE shall separately report PRODUCTS sold and PRODUCTS otherwise disposed
of pursuant to Section 1.07 plus a computation of royalty amount due with
respect thereto for the applicable quarter for LICENSEE, each AFFILIATE, and
each sublicensee. At LICENSEE'S option, each AFFILIATE shall provide a written
report directly to LICENSOR setting forth the NET SALES PRICE with respect to
PRODUCTS for the applicable quarter. The AFFILIATE shall separately report
PRODUCTS sold and PRODUCTS otherwise disposed of pursuant to Section 1.07 plus
computation of Royalty amounts due with respect thereto for the applicable
quarter. Any reports required to be submitted pursuant to Section 6.00 hereof
may be consolidated with any report submitted pursuant to Section 6.0 of the
FIRST LICENSE AGREEMENT.

      6.01 The Royalty shall be payable in currency of the United States of
America regardless of the country where earned and shall be paid or deposited as
designated in writing by LICENSOR. The exchange rate used to calculate the
amounts due pursuant to Sections 3.01 and 5.03 shall be the same rate specified
under Financial Accounting Standards Board Statement 52, or its successor, used
to translate the financial results of LICENSOR or its AFFILIATES for public
reporting.

      6.02 If the Royalty for the previous calendar quarter remains unpaid
thirty (30) days after the end of such calendar quarter, interest shall accrue
on such unpaid amount at the lower of (a) fifteen percent (15%) per annum, or
(b) the highest rate permitted by law, until paid.

      6.03 Intentionally omitted.

      6.04 If this Agreement is for any reason terminated before all of the
payments herein provided for have been made, LICENSEE shall immediately submit a
terminal report and pay to LICENSOR any remaining unpaid balance even though the
due date as above provided has not been reached.

      6.05 Prior to the execution of any agreement (the "DISTRIBUTION
AGREEMENT") between LICENSEE and Harvest Technologies, Inc. ("HARVEST"),
granting LICENSEE the right to distribute products purchased from HARVEST for
sale or use in the ADDITIONAL LICENSED FIELDS, the parties agree that all
royalties paid by LICENSEE under any agreement with LICENSOR shall be deemed to
relate exclusively to the ORIGINAL LICENSED FIELDS. For the first four full
calendar quarters following the execution of a DISTRIBUTION AGREEMENT between
HARVEST and LICENSEE, all royalties paid by LICENSEE under any agreement with
LICENSOR shall be deemed to relate 80% to the ORIGINAL LICENSED FIELDS and 20%
to the ADDITIONAL LICENSED FIELDS. Within 90 days following the end of said four
calendar quarters, LICENSEE shall conduct a randomized sampling of a limited
number of users of its PRODUCT to solely determine the sales allocable to the
ORIGINAL LICENSED FIELDS and the sales allocable to the ADDITIONAL LICENSED
FIELDS. Such randomized sampling shall be of LICENSEE'S sole design, regardless
of whether the sampling is performed by LICENSEE or any other third party, and
LICENSEE shall bear all costs associated with such sampling; provided, however,
that if the sampling is conducted by a third party, then LICENSOR shall directly
pay LICENSEE up to $15,000 per sampling to cover the costs of such sampling
(following submission to LICENSOR of proof of payment for such services by
LICENSEE). The resultant percentage allocation of sales between these licensed
fields resulting from the sampling procedures shall be conclusively deemed for
the succeeding four calendar quarters to be the percentages of royalties payable
on account of sales in the ORIGINAL LICENSED FIELDS and the ADDITIONAL LICENSED
FIELDS. LICENSOR shall not use the sampling information against LICENSEE in any
way or have any cause of action against LICENSEE and LICENSEE shall have no
liability whatsoever to LICENSOR for the manner in which the sampling is
conducted. LICENSOR hereby indemnifies and holds LICENSEE harmless against any
third party claims that LICENSEE has interfered with any obligations of LICENSOR
to such third party.

<PAGE>

      6.06 Commencing April 1, 2005 through execution of a DISTRIBUTION
AGREEMENT, LICENSEE shall be entitled to take as a credit against royalty
payments made in respect of the ORIGINAL LICENSED FIELDS an amount equal to
$6,250 per calendar quarter (or any pro rated period thereof through execution
of a DISTRIBUTION AGREEMENT). Following execution of a DISTRIBUTION AGREEMENT,
LICENSEE shall be entitled to take as a credit against royalty payments made in
respect of the ORIGINAL LICENSED FIELDS an amount equal to $12,500 per calendar
quarter (or any pro rated period thereof), with said credit to be applied first
against royalties paid (or presumed under Section 6.05 hereof to be paid) in
respect of the ADDITIONAL LICENSED FIELDS, and the remainder (if any) applied
against royalties paid (or presumed under Section 6.05 hereof to be paid) in
respect of the ORIGINAL LICENSED FIELDS.

VII.  CONFIDENTIALITY

      7.00 No party to this Agreement shall disclose to any third party nor use
for any purpose, other than the purpose of this Agreement information or data
received from a Party under this Agreement without prior written approval from
the Party from whom the information or data was received.

      7.01 The obligations of non-disclosure and non-use shall apply for a
period of five (5) years following the expiration or termination of this
Agreement, but shall not apply to any information or data which receiving Party
can show by competent proof:

            (a)   is known to the public prior to disclosure hereunder;

            (b)   becomes known to the public through no fault of the receiving
                  Party;

            (c)   was known to the receiving Party prior to disclosure under
                  this Agreement;

            (d)   is disclosed to the receiving Party by a third party having a
                  legal right to make such disclosure;

            (e)   is reasonably required to be disclosed to further the purposes
                  of this Agreement, including to file for registration, to file
                  patent applications, and to contact with third parties under
                  an obligation of confidentiality to further the development of
                  the Licensed Product;

            (f)   is required to be disclosed to a regulatory agency of
                  competent jurisdiction consistent with the receiving Party's
                  past practice, provided that if such agency is not required by
                  law to maintain the confidentiality of such information, then
                  the disclosing Party shall first be given the opportunity to
                  intervene and contest the disclosure or seek appropriate
                  protection.

      7.02 The parties agree that information disclosed during the negotiation
of this Agreement is to be considered confidential.

      7.03 Information disclosed by LICENSEE to LICENSOR or otherwise obtained
by LICENSOR under this Agreement shall only be used by LICENSOR for the purpose
of determining compliance under this Agreement by LICENSEE, sublicensees, or
users or purchasers of PRODUCT, and not for any other purpose.

<PAGE>

VIII. REPRESENTATIONS AND DISCLAIMER OF WARRANTIES

      8.00 LICENSOR SHALL HAVE NO LIABILITY WHATSOEVER TO LICENSEE FOR OR ON
ACCOUNT OF ANY INJURY, LOSS, OR DAMAGE, OF ANY KIND OR NATURE SUSTAINED BY, OR
ANY DAMAGE ASSESSED OR ASSERTED AGAINST, OR ANY OTHER LIABILITY INCURRED BY OR
IMPOSED UPON LICENSEE, ARISING OUT OF OR IN CONNECTION WITH OR RESULTING FROM
(A) THE PRODUCTION, USE, OR SALE OF ANY APPARATUS OR PRODUCT, OR THE PRACTICE OF
THE PATENTS, OR (B) ANY ADVERTISING OR OTHER PROMOTIONAL ACTIVITIES WITH RESPECT
TO ANY OF THE FOREGOING.

      8.01 LICENSOR agrees not to abandon, and agrees to pay all taxes and fees
necessary to maintain PATENTS hereunder, in the United States and all other
countries. In the event LICENSOR elects not to pay any maintenance or file for
renewal any of the PATENTS, LICENSOR shall notify LICENSEE, in writing, of
LICENSOR'S intention sufficiently in advance of the date by which such payment
or filing is due to afford LICENSEE a reasonable opportunity to pay such fee or
file such renewal, and LICENSOR shall cooperate with LICENSEE in doing so.

      8.02 Intentionally Omitted.

      8.03 LICENSOR expressly represents and warrants that it has the full power
and authority to enter into this Agreement and to carry out the transaction
contemplated hereby. Licensor further represents and warrants that no academic
institution (other than the University of Minnesota which has a non-exclusive
perpetual license to the PATENTS solely in connection with not-for-profit
research and teaching), member of an academic institution, corporation or any
local, state or federal government holds any property rights through it in the
subject matter of this Agreement, and that it is able to consummate this
Agreement in the capacity of a free agent.

      8.04 LICENSOR herein represents, covenants, and warrants that it is
co-owner of the entire right, title, and interest in the PATENTS with the
University of Minnesota. The University of Minnesota has assigned all rights to
the PATENTS but has retained a non-exclusive perpetual license to the PATENTS
solely in connection with not-for-profit research and teaching. LICENSOR further
warrants that no existing prior agreement or assignment presently conflicts in
any manner with the present Agreement or otherwise prevents LICENSOR from
fulfilling all of its obligations under this Agreement. A copy of LICENSOR's
assignment of U.S. Patent Number 5,165,938 is attached as Appendix CC.

      8.05 LICENSOR further covenants, warrants and represents that, except for
the University of Minnesota non-exclusive perpetual license to the PATENTS
solely in connection with not-for-profit research and teaching, it has the sole
right to grant, for the LICENSED TERRITORY, licenses under all PATENTS.

      8.06 LICENSOR further represents and warrants that it believes each claim
of its PATENTS is valid and enforceable.

IX.   TAXES, GOVERNMENT APPROVALS, AND LIABILITY

      9.00 LICENSEE shall be solely responsible for the payment and discharge of
any taxes, duties, or withholdings relating to any transaction of LICENSEE in
connection with the manufacture, use, sale, lease, or other commercialization of
a portion of the PRODUCTS, if done by LICENSEE. LICENSOR is solely responsible
for any and all taxes, annuities, and fees levied by the authorities to maintain
the PATENTS and for the receipt of any and all payment by third parties to
LICENSOR because of the PATENTS.

      9.01 LICENSEE shall be responsible for all PRODUCT liability and PRODUCT
warranty for any PRODUCTS manufactured for or by LICENSEE under this Agreement
and shall insure this risk accordingly.

<PAGE>

X.    TERMINATION

      10.00 This Agreement shall terminate upon the expiration of the last to
expire of the valid and enforceable PATENTS included herein, or upon the
abandonment of the last to be abandoned of any patent applications included
herein, whichever is later, unless the Agreement is sooner terminated.

      10.01 Subsequent to the termination of this Agreement under Section 10.04,
LICENSEE agrees that it will not practice under the PATENTS. Notwithstanding the
foregoing, LICENSEE may, after the effective date of such termination, sell all
PRODUCTS which may be in inventory and not sold; provided, however, LICENSEE
provides any reports and payments required by Section 6.00 of this Agreement.

      10.02 If either party shall be adjudged bankrupt, or become insolvent, or
make an assignment for the benefit of creditors, or be placed in the hands of a
receiver or a trustee in bankruptcy, the other party may terminate this
Agreement by giving sixty (60) days notice by Registered Mail to the other
party, specifying the basis for termination. If within sixty (60) days after the
receipt of such notice, the party receiving notice shall remedy the condition
forming the basis for termination, such notice shall cease to be operative, and
this Agreement shall continue in full force.

      10.03 The word "termination" and cognate words, such as "term" and
"terminate," used in this Article X and elsewhere in this Agreement are to be
read, except where the contrary is specifically indicated, as omitting from
their effect the following rights and obligations, all of which survive any
termination to the degree necessary to permit their complete fulfillment or
discharge:

            a.    LICENSEE'S obligation to supply a terminal report as specified
                  in Section 6.04 of this Agreement.

            b.    LICENSOR'S right to receive or recover and LICENSEE'S
                  obligation to pay Royalties accrued or accruable for payment
                  at the time of any termination.

            c.    LICENSEE'S obligation to maintain records under Section 12.0
                  of this Agreement.

            d.    Any cause of action or claim of LICENSOR accrued, or to
                  accrue, because of any breach or default by LICENSEE.

            e.    The representation and disclaimer of warranties of Section
                  8.00.

            f.    The PRODUCT liability, PRODUCT warranty, and indemnification
                  of Section 9.02.

            g.    The obligations of confidentiality of Sections 7.00 and 7.01.

      10.04 Termination for Cause. Either party shall have the right to begin
proceedings to terminate this Agreement in the event that the other party
breaches or defaults in the performance of any of the terms of this Agreement.
The non-breaching party shall give the breaching party thirty (30) days written
notice of such breach and intention to terminate, stating in such notice the
grounds for such intention, provided, however, that if such breach or default is
remediable and if the breaching party shall, within said thirty (30) day period,
remedy or is proceeding diligently to the non-breaching party's reasonable
satisfaction to remedy such breach or default, then this Agreement shall remain
in full force and effect. If the breaching party does not, within said thirty
(30) day period remedy such breach to the reasonable satisfaction of the
nonbreaching party, the non-breaching party may, at its option, terminate this
Agreement. Moreover, if, however the alleged breaching party responds within the
30 days of receiving the above notice by either denying the existence of the
breach or asserting that the breach has been cured, then the alleged breaching
party has a right to arbitrate the matter of the breach and/or cure under
Article XXIII of this Agreement, and such disputed issues will be settled by
such arbitration prior to any further attempt to terminate this Agreement under
this Article. Only upon a finding of an arbitrator under Article XXIII that a
material breach has occurred and has not been cured may the non-breaching party
then terminate this Agreement under this Article. If and when such finding of an
uncured material breach has been made by the arbitrator, the non-breaching party
shall have the right and option to terminate this Agreement by giving the
breaching party thirty (30) days written notice of the termination stating in
such notice the grounds for such termination; provided, however, that if such
breach or default is remediable and if the breaching party shall, within said
thirty (30) day period remedy or is proceeding diligently to the non-breaching
party's reasonable satisfaction to remedy such breach or default, then this
Agreement shall remain in full force and effect.

<PAGE>

      10.05 Termination of this Agreement shall not limit either party from
pursuing any other remedies otherwise available to it, including, without
limitation, injunctive relief.

      10.06 LICENSEE shall have a right to terminate this Agreement upon 180
days written notice to LICENSOR.

XI.   LITIGATION

      11.00 LICENSOR may, at its own expense, bring suit or take any other
action it deems appropriate in its sole and absolute discretion against any
infringer in the ADDITIONAL LICENSED FIELDS and LICENSOR shall be entitled to
all past, present, or future recoveries that in any way result from or relate to
such suit or action.

XII.  RECORDS

      12.00 LICENSEE and sublicensees shall keep accurate records showing the
sales or other disposition of PRODUCT sold or otherwise disposed of under the
license herein granted in sufficient detail to enable the compliance with the
terms of this SECOND LICENSE AGREEMENT to be determined, and shall permit
LICENSOR or its duly authorized agent to inspect all such records and to make
copies of or extracts from such records during regular business hours throughout
the term of this Agreement and for a reasonable period of not less than three
(3) years thereafter.

      12.01 LICENSEE and sublicensees shall keep proper books of account with
reference to their use of the PATENTS and to all PRODUCTS which it may use or
sell. LICENSEE shall provide LICENSOR with a quarterly written report reconciled
to its quarterly Royalty. This report shall be in a format acceptable to
LICENSOR and LICENSEE.

      12.02 In case LICENSOR does not accept the statements of sales performed
by LICENSEE, and sublicensees and the parties cannot reach an agreement within
thirty (30) days after LICENSOR'S notification of disagreement, LICENSOR is
authorized to have audited by a certified public accountant bound by
professional secrecy the documents relevant for computing the fee. This auditor
shall have the right to inspect all books and records of LICENSEE and
sublicensees directly related to the Product, its manufacturing or sale. The
auditing costs shall be borne by LICENSOR unless the auditing proves the failure
of LICENSEE to provide LICENSOR with correct statement of sales performed. In
the latter case LICENSEE shall pay the costs of the auditing if the statement of
sales is in error in excess of five percent (5%) of the amounts due to LICENSOR.

XIII. NONASSIGNABILITY

      13.00 This Agreement or any interest herein shall not be assigned or
transferred, in whole or in part, by either party hereto without the prior
written consent of the other party hereto. However, without securing such prior
written consent, either party may assign this Agreement to an AFFILIATE or a
successor of all or substantially all of its business to which this Agreement
related provided, that no such assignment shall be binding and valid until and
unless the assignee shall have assumed in a writing, delivered to the
non-assigning party, all of the duties and obligations of the assignor. If the
LICENSEE is the assignor, then the LICENSEE shall remain liable and responsible
to the non-assigning party hereto for the performance and observance of all such
duties and obligations. If the LICENSOR is the assignor, the LICENSOR shall give
written notice to LICENSEE of any assignment of any of the PATENTS.

<PAGE>

XIV.  SEVERABILITY

      14.00 The parties agree that if any part, term, or provision of this
Agreement shall be found illegal or in conflict with any valid controlling law,
the validity of the remaining provisions shall not be affected thereby.

      14.01 In the event the legality of any provision of this Agreement is
brought into question because of a decision by a court of competent
jurisdiction, LICENSOR, by written notice to LICENSEE, may revise the provision
in question or may delete it entirely so as to comply with the decision of said
court.

XV.   NON-USE OF LICENSOR'S NAME

      15.00 In publicizing anything made, used, offered for sale, sold, or
imported under this Agreement, LICENSEE shall not use the name of LICENSOR or
otherwise refer to any organization related to LICENSOR, except with the written
approval of LICENSOR. The parties covenant and agree that, except as provided
for herein below, each will not from and after the date hereof make, issue or
release any public announcement, press release, statement or acknowledgment of
the existence of, or reveal publicly the terms, conditions and status of, the
transactions contemplated herein, without the prior written consent of the other
party as to the content and time of release of and the media in which such
statement or announcement is to be made; provided, however, that in the case of
announcements, statements, acknowledgments or revelations which either party is
required by law to make, issue or release, the making, issuing or releasing of
any such announcement, statement, acknowledgment or revelation by the party so
required to do so by law shall not constitute a breach of this Agreement. One
party shall not use the name or trademarks of the other party or any of its
Affiliates for advertising or promotional purposes without the prior written
consent of the other party. In furtherance of the foregoing, neither party shall
originate any publicity or other announcement, written or oral, whether to the
public, the press, the trade, or otherwise, relating to this Agreement or the
existence of an arrangement between the parties, without the prior written
approval of the other party.

XVI.  INDEPENDENCE OF PARTIES

      16.00 This Agreement shall not constitute the designation of either party
as the representative or agent of the other, nor shall either party by this
Agreement have the right or authority to make any promise, guarantee, warranty,
or representation, or to assume, create, or incur any liability or other
obligation of any kind, express or implied, against or in the name of, or on
behalf of, the other, except as described herein.

XVII. WAIVER, INTEGRATION, ALTERATION

      17.00 The waiver of a breach hereunder may be effected only by a writing
signed by the waiving party and shall not constitute a waiver of any other
breach.

      17.01 This Agreement represents the entire understanding between the
parties, and supersedes all other agreements, express or implied, between the
parties concerning PATENTS.

      17.02 A provision of this Agreement may be altered only by a writing
signed by both parties, except as provided in Sections 14.00 and 14.01, above.

XVIII. INTENTIONALLY OMITTED

XIX.  FORCE MAJEURE

      19.00 The obligations of either party to perform under this Agreement
shall be excused if such failure to perform or any delay is caused by acts of
God, civil commotion, riots, war, revolution, fire, explosion, flood, compliance
with or other action taken to carry out the intent or purpose of any law or
regulation, or any other cause reasonably beyond the control of the party
obligated to perform. Upon the occurrence of such an event, the duties and
obligations of the parties shall be suspended for the duration of the event
preventing proper performance under this Agreement, provided, however, that if
such suspension shall continue in excess of sixty days, the parties shall meet
and attempt to arrive at a mutually acceptable compromise within the spirit and
intent of this Agreement.

<PAGE>

XX.      JURISDICTION

      20.00 This Agreement shall be construed in accordance with the substantive
laws of the State of Illinois of the United States of America.

XXI.  NOTICES UNDER THE AGREEMENT

      21.00 For the purpose of all written communications and notices between
the parties, their addresses shall be:

            LICENSOR:               Cytomedix, Inc.
                                    416 Hungerford Drive, Suite 330
                                    Rockville, Maryland 20850
                                    Attention:  Dr. Kshitij Mohan

            With a copy to:         Steven R. Jakubowski
                                    Robert F. Coleman & Associates
                                    77 West Wacker Drive, Suite 4800
                                    Chicago, Illinois 60601

            LICENSEE:               DePuy Spine, Inc.
                                    325 Paramount Drive
                                    Raynham, Massachusetts 02767
                                    Attention:  Earl Fender, Worldwide President

            With a copy to:         Chief Patent Counsel
                                    Johnson & Johnson
                                    One Johnson & Johnson Drive
                                    New Brunswick, New Jersey 08933

or any other addresses of which either party shall notify the other party in
writing.

XXII. MARKING

      22.00 To the extent legally permissible and/or legally mandated, LICENSEE
agrees to mark its brochures for the items listed in Appendix BB (revised and
attached hereto) and improvements thereof with the following: "Certain products
shown in this brochure are sold subject to a License Agreement with Cytomedix
Inc., and are not licensed for use in with chronic non-healing wounds (i.e., any
venous stasis, decubitus, or diabetic foot ulcers, or any other wounds lasting
30 days or longer).

<PAGE>

XXIII. ARBITRATION

      23.00 Except in the event of any litigation or proceeding commenced by any
third party against the LICENSOR or the LICENSEE in which the other party is an
indispensable party or potential third party defendant, and except for
enforcement of a party's remedies to the extent such enforcement must be
pursuant to court authorization or order under applicable State law in Illinois
or any State having jurisdiction, any controversy or claim arising out of or
relating to this Agreement or the validity, inducement, or breach thereof, shall
be settled by arbitration prior to any attempt to terminate the Agreement. Any
controversy or claim arising out of or relating to this Agreement or the
validity, inducement, or breach thereof, shall be settled by arbitration before
a single arbitrator in accordance with the Commercial Arbitration Rules of the
American Arbitration Association ("AAA") then pertaining, except where those
rules conflict with this provision, in which case this provision controls. The
parties hereby consent to the jurisdiction of the federal district court for the
district in which the arbitration is held for the enforcement of this provision
and the entry of judgment on any award rendered hereunder. Should such court for
any reason lack jurisdiction, any court with jurisdiction shall enforce this
clause and enter judgment on any award. The arbitrator shall be an attorney who
has at least 15 years of experience with a law firm or corporate law department
of over 25 lawyers or was a judge of a court of general jurisdiction. The
arbitration shall be held in Chicago, Illinois and in rendering the award the
arbitrator must apply the substantive law of State of Illinois (except where
that law conflicts with this clause), except that the interpretation and
enforcement of this arbitration provision shall be governed by the Federal
Arbitration Act. The arbitrator shall be neutral, independent, disinterested,
impartial and shall abide by The Code of Ethics for Arbitrators in Commercial
Disputes approved by the AAA. Within 45 days of initiation of arbitration, the
parties shall reach agreement upon and thereafter follow procedures assuring
that the arbitration will be concluded and the award rendered within no more
than eight months from selection of the arbitrator. Failing such agreement, the
AAA will design and the parties will follow procedures that meet such a time
schedule. Each party has the right before or, if the arbitrator cannot hear the
matter within an acceptable period, during the arbitration to seek and obtain
from the appropriate court provisional remedies such as attachment, preliminary
injunction, replevin, etc., to avoid irreparable harm, maintain the status quo
or preserve the subject matter of the arbitration. THE ARBITRATOR SHALL NOT
AWARD ANY PARTY PUNITIVE, EXEMPLARY, MULTIPLIED OR CONSEQUENTIAL DAMAGES, AND
EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT TO SEEK SUCH DAMAGES. NO PARTY
MAY SEEK OR OBTAIN PREJUDGMENT INTEREST OR ATTORNEYS' FEES OR COSTS. Nothing in
this agreement shall limit the right of either party, before and during such
arbitration, to have recourse to such to such judicial remedies, including
preliminary injunction and attachment, as would be available in the absence of
this clause.

      23.01 Discovery shall be allowed pursuant to the intendment of the Federal
Rules of Civil Procedure and as the arbitrators determine appropriate under the
circumstances.

<PAGE>

      IN WITNESS WHEREOF, the parties have caused this SECOND LICENSE AGREEMENT
to be duly executed as of the date first mentioned above via their telefaxed
signatures, which shall have the same import and effect as if signed originally.

LICENSOR                           LICENSEE
Cytomedix, Inc.                    DePuy Spine, Inc. (f/k/a DePuy AcroMed, Inc.)

By:  Kshitij Mohan, Ph.D.          By:  Earl Fender

Name:  Kshitij Mohan, Ph.D         Name:  Earl Fender

Its:  Chief Executive Officer      Its:  Worldwide President

<PAGE>

                                   APPENDIX AA

U.S. Patent No. 5,165,938 entitled "Wound Healing Agents," issued 11/24/92,
expires 11/19/2009

Australia Patent No. 596,954 entitled "Wound Healing Agents," issued 11/8/85,
expires 11/8/2005

Canada Patent No. 1,261,259 entitled "Wound Healing Agents issued 9/26/89,
expires 9/26/2006

Europe Patent No. 202,298 entitled "Wound Healing Agents," issued 7/15/92
(validated in Belgium, France, Germany, Great Britain, Netherlands, and Sweden),
expires 11/8/2005

Israel Patent No. 77,096 entitled "Wound Healing Agents," issued 11/19/85,
presently expired.

Ireland Patent No. 57,894 entitled "Wound Healing Agents," issued 5/5/93,
expires 11/8/2005

Japan Patent No. 1,986,949 entitled "Wound Healing Agents," issued 3/8/95,
expires 11/8/2005

<PAGE>

                                   APPENDIX BB

                             (Schedule of Products)

SEPARATORS

2761-02-020       SYMPHONY II FS-20 Blood Draw and Processing Components

2761-02-060       SYMPHONY II FS-60 Blood Draw and Processing Components

2761-02-120       SYMPHONY II FS-120 Blood Draw and Processing Components

2760-40-101       SYMPHONY Process Disposable-One

2760-40-102       SYMPHONY Process Disposable-Two

Disposable Processing Kits contain the items required for containing blood
during processing in the centrifuge

CAPITAL

2761-02-000       SYMPHONY II Centrifuge with Balance Weight Set

2760-40-000       SYMPHONY Centrifuge

APPLICATORS/MIXERS

2760-40-202       SYMPHONY Spray Applicator

2760-40-204       SYMPHONY Dual Lumen Applicator

2760-50-000       SYMPHONY GDS Standard Kit

2760-50-100       SYMPHONY GDS Manifold Kit

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]